Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Change in Receivables: 2020-2025

Historic Change in Receivables for Fulcrum Therapeutics (FULC) over the last 4 years, with Jun 2025 value amounting to -$979,000.

  • Fulcrum Therapeutics' Change in Receivables fell 141.96% to -$979,000 in Q2 2025 from the same period last year, while for Jun 2025 it was -$2.3 million, marking a year-over-year decrease of 239.12%. This contributed to the annual value of $1.6 million for FY2024, which is 406.17% up from last year.
  • According to the latest figures from Q2 2025, Fulcrum Therapeutics' Change in Receivables is -$979,000, which was up 12.35% from -$1.1 million recorded in Q1 2025.
  • In the past 5 years, Fulcrum Therapeutics' Change in Receivables registered a high of $2.6 million during Q4 2021, and its lowest value of -$5.0 million during Q4 2022.
  • Moreover, its 3-year median value for Change in Receivables was -$103,000 (2023), whereas its average is -$22,900.
  • Data for Fulcrum Therapeutics' Change in Receivables shows a peak YoY increase of 1,840.79% (in 2024) and a maximum YoY decrease of 3,527.91% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Fulcrum Therapeutics' Change in Receivables stood at $2.6 million in 2021, then tumbled by 291.37% to -$5.0 million in 2022, then skyrocketed by 99.14% to -$43,000 in 2023, then slumped by 3,527.91% to -$1.6 million in 2024, then crashed by 141.96% to -$979,000 in 2025.
  • Its last three reported values are -$979,000 in Q2 2025, -$1.1 million for Q1 2025, and -$1.6 million during Q4 2024.